openwiki-wiki/commitments.md

type, title, description, tags

type	title	description	tags
Reference	Commitments	Active work tasks, follow-ups, approvals, and scheduled items extracted from sources (web-search, git-repo, literature flywheel-sync, etc.). Personal errands live in /personal-logistics.md instead.	commitments work follow-ups distributors-2026-08-07-refresh dong-huiqun-ji-nan-chengquan-link

Commitments

Concrete work tasks, follow-ups, approvals, and scheduled items extracted from Gmail, Notion, Slack, direct mentions, and other work-relevant sources. Personal errands and life admin live in /personal-logistics.md instead.

Active

china-cde-cell-gene-therapy-rules-2026: verify CDE classification scope for Chinese pharma / CDMO conversations

• Owner: me
• Source: web-search — cisema.com 2026-07-24 (China CDE Defines Classification Rules for Cell & Gene Therapy Drugs)
• Due: unscheduled
• Status: open
• Notes: Single credible regulatory-trade source. Pull the NMPA/CDE-direct release before the next vendor sync; check whether any active CellShot-TriArm or ClinoReactor-class deals depend on the new classification scope.

celvivo-clinoreactor-thewell-bioscience-xeno-free: verify TheWell Bioscience co-marketing signal on next CelVivo check

• Owner: me
• Source: web-search — thewellbio.com 2026-07-21 / 2026-07-23 / 2026-07-25 (Xeno-Free Cell Culture Media, Stem Cell Culture Product Guide, Apical-Out Organoids white paper — all explicitly name "CelVivo ClinoReactor™")
• Due: unscheduled
• Status: open
• Notes: First vendor-anchored CelVivo ClinoReactor signal in any Tavily pull (prior pulls returned only MO:BOT / generic organoid). TheWell Bioscience is a hydrogel-media partner; their workflow pages position ClinoReactor as the scale-up vessel for apical-out organoids + hMSC expansion. Confirm with CelVivo whether this is a sanctioned co-marketing arrangement and whether it maps to any active Chinese pharma / CDMO deal.

china-order-no-818-clinical-translation: verify Order No. 818 (effective 2026-05-01) scope for Chinese pharma / CDMO conversations

• Owner: me
• Source: web-search — BetaLife LinkedIn 2026-07 (top score 0.779; explicitly cites "Order No. 818, effective May 1, 2026" with accelerated clinical-translation pathway); Tavily answer text corroborates; Roots Analysis re-mentions broader China cell-therapy regulatory pattern
• Due: unscheduled
• Status: open
• Notes: Single primary source (BetaLife SG LinkedIn) but the regulation itself is a published policy text — Order No. 818 creates an accelerated clinical-translation pathway at qualified hospitals for cell therapy and 3D bioprinting after demonstrating safety and preliminary efficacy. This is the clinical-translation counterpart to the existing china-cde-cell-gene-therapy-rules-2026 item (which is about classification / CMC planning). Both items matter: classification scope drives dossier content vendors need to assemble; the clinical-translation pathway drives which hospitals can host first-in-human studies. Pull the NMPA / State Council Order No. 818 direct text before the next vendor sync; check whether any active CellShot-TriArm or ClinoReactor-class deal depends on whether the buyer hospital qualifies as a "qualified hospital" under the regulation.

cellink-bio-x-gen3-customer-evidence: verify Cellink BIO X Gen 3 / BIO X6 customer pipeline on next Cellink check

• Owner: me
• Source: web-search — Nuclear Mechano-Oncology LinkedIn 2026-07 (score 0.601; "our new BIO X Gen 3 bioprinter has now been installed … first hands-on training session"); CELLINK official LinkedIn 2026-07-28 (score 0.287; BIO X6 at University of Miami 3D Bioprinting Facility); third-party market report LinkedIn 2026-07-28 (score 0.659; Cellink revenue uptick following strategic acquisitions); appellaser.ro practical selection guide 2026-07-24 (score 0.303; BIO X Gen 3 general-purpose positioning)
• Due: unscheduled
• Status: open
• Notes: First vendor-anchored Cellink signal in any Tavily pull after 5 prior pulls of zero Cellink product mentions. Four distinct sources: customer install LinkedIn (Eastern Europe), vendor LinkedIn (CELLINK U. Miami), market report, independent selection guide. Verify with Cellink whether the BIO X Gen 3 / BIO X6 nomenclature is current product naming or if one is being deprecated; whether any of the named customer accounts (Nuclear Mechano-Oncology; U. Miami 3D Bioprinting Facility) maps to active Chinese pharma R&D / CDMO opportunities. Companion to the existing celvivo-clinoreactor-thewell-bioscience-xeno-free item.

china-cgt-2026-july-developments: monitor gene-editing trial death fallout + Merck–Bio-Techne / CARsgen satri-cel context for Chinese pharma / CDMO positioning

• Owner: me
• Source: web-search — Straits Times 2026-07-24 (score 0.313; patient death in China gene-editing trial draws fire); LiveScience 2026-07-24 (score 0.145; 6-year-old girl, investigation into gene-therapy regulations); SCMP 2026-07-29 (score 0.203; "Fear of policy backlash" — same-day coverage with this Tavily pull); Roots Analysis 2026-07-24 (score 0.669; Merck–Bio-Techne $11.3B acquisition June 2026 + CARsgen satri-cel CAR-T approval for stomach cancer June 2026); BioSpace 2026-07-27 (score 0.535; Summit/Merck China-first regulatory navigation)
• Due: unscheduled
• Status: open
• Notes: Material new development in the China regulatory lane — sits on top of the existing china-cde-cell-gene-therapy-rules-2026 and china-order-no-818-clinical-translation items, not replacing them. Two positive signals (Merck–Bio-Techne acquisition; CARsgen satri-cel solid-tumor CAR-T approval) show the China CGT manufacturing environment is consolidating around advanced therapeutics. One negative signal (gene-editing trial death + published regulatory backlash) could foreshadow stricter CDE / NMPA / hospital-level oversight and tighter qualification criteria for "qualified hospitals" under Order No. 818. Together these affect: (a) qualification timelines for the CellShot-TriArm and ClinoReactor-class deals Robin has in flight, (b) which "qualified hospitals" remain eligible to host first-in-human studies, (c) whether CelVivo / 3Brain / Cellink vendor positioning for Chinese pharma R&D / CDMO accounts needs to change tone (e.g. emphasize safety documentation, IRB-grade workflows). Pull NMPA / hospital-IRB statements on the gene-editing trial case before next Chinese customer conversation.

3brain-coreplate-2026-conference-positioning: verify current CorePlate campaign and retrieve application material on next 3Brain check

• Owner: me
• Source: web-search — 3Brain official website plus 3Brain organization material captured through LinkedIn in Tavily pull 7 (2026-07-30); the dated result is 2026-07-25 and names ISSCR 2026 booth 412, while the company page also names ELRIG Drug Discovery booth 4. Tavily pull 11 (2026-08-03) adds a 3Brain LinkedIn post dated 2026-07-29 ("3Brain contributes to Utrecht Summer School course on Human Brain Models", score 0.808) — the first Tavily pull where the 3Brain answer text is not mis-attribution — and the 3Brain AG company LinkedIn page (score 0.839)
• Due: unscheduled
• Status: open
• Notes: First credible direct 3Brain evidence after five Tavily pulls dominated by an unrelated EEG-paper mis-attribution. Vendor material positions CorePlate-enabled HD-MEA for high-resolution, scalable functional readouts from iPSC neuronal/cardiac models, brain organoids, assembloids, and 3D spheroids. Pull 11 extends the vendor-channel strand to the academic / training segment (Utrecht Summer School "Human Brain Models" course) on top of the ISSCR / ELRIG conference-booth strand from pull 7. Confirm which conference posts are current, obtain the named posters / application notes / Utrecht course module, and map them to Chinese neural-organoid and pharma-screening prospects. This pull does not establish CorePlate 1W/6W load force or Sample Holder Set details.

celvivo-clinostar-2-nams-demo-2026: verify product naming and campaign provenance on next CelVivo check

• Owner: me
• Source: web-search — Instagram snippets surfaced in Tavily pull 7 (2026-07-30): ClinoStar webinar copy (DbaUZjIjMgK), NexUs Locus on-site demo copy dated 2026-07-24 (DbKYC4NBtrN), and ClinoStar 2 NAMs positioning (DbSl7nkoFjK). Tavily pull 11 (2026-08-03) adds an independent confirmation from an Indian distributor event page (labindia-analytical.com News & Events, score 0.696) that CelVivo is exhibiting at Thailand Lab 2026 (Bangkok, 2026-09-02 → 2026-09-04) and that ClinoStar 2 is current product naming with oxygen regulation as a distinguishing feature
• Due: unscheduled
• Status: open
• Notes: Watchlist lead, not a confirmed launch or customer win. Verify that the posts come from CelVivo or an authorized distributor, whether ClinoStar 2 is current official product naming, and whether the NexUs Locus live demo produced reusable data or contacts. Pull 11's labindia-analytical.com result is the first non-Instagram, named-event confirmation of ClinoStar 2 + Thailand Lab 2026; treat it as independent corroboration, not vendor-direct. The result set does not support Tavily's “installed base” language; one malformed duplicate URL was discarded.

cellink-volumetric-lumen-x-release: verify CELLINK × Volumetric new Lumen X release on next Cellink check

• Owner: me
• Source: web-search — Tavily pull 11 (2026-08-03) top hit on Cellink BIO X bioprinter 2026: 3DPrint.com 2026-07-28 (score 0.819) "CELLINK and Volumetric Release New Lumen X for Lumen X Bioprinting". Tavily answer text corroborates and adds BioMET '26 Vellore India (2026-08-05 → 2026-08-07) showcase detail. Companion evidence: Cellink LinkedIn 2026-07-29 (score 0.762) BioMET '26 exhibiting post; CELLINK Facebook 2026-07-28 (score 0.632) second-conference post
• Due: unscheduled
• Status: open
• Notes: First credible direct Cellink product / partnership release evidence on the Robin portfolio after 10 prior Tavily pulls dominated by mis-attribution or BIO X Gen 3 / BIO X6 customer evidence (see existing cellink-bio-x-gen3-customer-evidence). Lumen X is in Robin's portfolio table ("Cellink — BIO X / BIONOVA X / Lumen X"). Verify with Cellink: (a) what is the relationship between CELLINK and Volumetric — co-marketing, OEM, distribution, or full acquisition; (b) is "New Lumen X" a distinct SKU from the original Lumen X (volumetric DLP) or a refresh; (c) does BioMET '26 Vellore presence map to any active Chinese pharma R&D / CDMO / biotech opportunities (likely India-channel rather than China-channel — adjacent to Robin's region); (d) does the existing cellink-bio-x-gen3-customer-evidence commitment's BIO X6 at U. Miami installation narrative change in light of this release.

itx-24h-host-build-2026-q3: finish assembly + Ubuntu + Hermes install on Robin's 24h host (paused since hardware is 10/11 arrived)

• Owner: me
• Source: git-repo — 03-Resources/ITX-24h-Host/ITX_24h_Host_v18_Config_2026-07-31.md (Obsidian vault, untracked as of fetch 2026-07-31T18:08:12Z)
• Due: unscheduled (waiting for the last #8 / #9 cable parts on hand; once on hand, finish the assembly + software stack)
• Status: open
• Notes: Personal-infra work item (workflow-tooling priority LOW), not vendor-anchored — logged here because it is source-anchored to Robin's actual vault work per the brief's commitments.md rule ("only real Robin commitments"). Plan: mATX + i5-12400 + DDR4-2666 32G + 板载 Realtek 1Gb + Intel PRO/1000 GT (¥2,985.82, 10/11 parts on hand). Two 网卡 VLAN: 192.168.31.100 → 主力机 Win 11 SSH, 10.10.10.254 → 主力 NAS RAGFlow. Post-assembly steps: Ubuntu Server 22.04 LTS install, partition / (GM7 512G) + /data (mSATA 512G), Docker, dual-NIC 静态 IP, 主力机 SSH key 免密, NAS RAGFlow API 接入, 安装 Hermes Agent, 24h 跑功耗 soak test. The host has no vendor-product overlap; not promoted to /themes.md row because that index is reserved for recurring workflow signals.

liu-2026-hd-mea-roadmap-implication: verify with 3Brain whether the Liu 2026 shape-conformal framework is on their product roadmap

• Owner: me
• Source: literature flywheel-sync 2026-08-08 — Liu N et al. (2026) Nature Biomedical Engineering, DOI 10.1038/s41551-026-01620-y, Wiki.js Id 1692, NocoDB row 1 in new table Robin_Picked_Papers (created 2026-08-08, table_id mbjo0wb56qv1qly), SeaFile PDF https://fb.biokingdom.top/f/6da50240729e41bdb369/?dl=1. Deep-read synthesis at /sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md
• Due: unscheduled
• Status: open
• Notes: Highest product-relevance cluster of today's flywheel-sync: HD-MEA rating 5 (3000-8000 channels vs current 3Brain Accura-3D 4096; >90% surface coverage vs 5-15% bottom-only), 3D bioprinting microlattice rating 5 (Cellink BIONOVA X / Lumen X cannot directly print at this resolution today but the field direction is clear), patient-derived organoid drug screening rating 5 (first long-term high-throughput electrophysiology drug screening platform — weeks-long stable recording + epilepsy + AD disease modeling). Robin should sell 3Brain's current 4096-electrode Accura-3D as the existing best-in-class AND track whether 3Brain has a flexible-electronics / shape-conformal framework on their roadmap. Companion question on /open-questions.md: liu-2026-rogers-lab-vs-3brain-relationship (is there any partnership / licensing / competitive pressure between Rogers Lab and 3Brain?). Companion commitment to verify with Cellink: liu-2026-cellink-microlattice-positioning (whether BIONOVA X or Lumen X can fabricate flexible-electronics-compatible microlattices).

miao-2025-celvivo-clinostar-positioning: fold Miao 2025 vHLPO co-differentiation story into CelVivo ClinoStar sales narrative

• Owner: me
• Source: literature flywheel-sync 2026-08-08 — Miao Y et al. (2025) Cell v2, DOI 10.1016/j.cell.2025.05.041, PMID 40592324, Wiki.js Id 1681, NocoDB row 93, SeaFile PDF https://fb.biokingdom.top/f/24704d54a95941449e2e/?dl=1. Deep-read synthesis at /sources/literature-miao-2025-cell-vascularization-v2-deepread.md
• Due: unscheduled
• Status: open
• Notes: Strongest CelVivo ClinoStar product relevance rating (5) in any of the 3 new flywheel-sync papers — the vHLPO single 3D EB co-induction (mesoderm+endoderm) protocol depends on 3D EB self-organization in low-shear rotating culture, which is exactly what ClinoStar provides. vHLPO 7% ECs vs traditional HLPO 0% is a clinically-meaningful differentiator that no competing 2D / static culture can match. Sales ammunition: "your lung organoid model is missing 100% of vasculature — ClinoStar co-differentiation gives you 7% ECs vs 0%". Cross-vendor co-marketing: CelVivo ClinoStar (culture) + Cellink BIO X (decellularized lung scaffold) + 3Brain HD-MEA (functional readout on the neural mesenchyme). Robin should fold this into the CelVivo industrial-customers program (existing CelVivo_中国工业客户开发研究报告 v1 + v2 in vault) and pitch to pediatric-hospital pharma R&D accounts (FOXF1 ACDMPV rare disease).

robin-picked-papers-nocodb-table: capture the structural change — new NocoDB table for Robin-handpicked papers

• Owner: me
• Source: literature flywheel-sync 2026-08-08 — Liu 2026 is the first entry in the new NocoDB table Robin_Picked_Papers (table_id mbjo0wb56qv1qly), created 2026-08-08 per Robin instruction to capture papers Robin hand-picks / provides outside the regular PubMed triage. The table is separate from the existing Organoid_Literature table.
• Due: unscheduled
• Status: open
• Notes: The new table has 9 fields: Title, DOI, Journal, Year, Authors, Source, wiki_url, pdf_url, deep_read_summary. Future handpicked papers should land in this table rather than in Organoid_Literature (which is PubMed-triage-driven). Verify with Robin: (a) what is the workflow for capturing a handpicked paper — manual PDF drop to /home/ldw/.hermes/cache/documents/ and then trigger the LDR pipeline; (b) should the LDR pipeline auto-route by signal (PubMed triage vs handpicked), or does Robin always provide the routing signal.

dong-huiqun-ji-nan-chengquan-link: confirm whether 董慧群 is a 济南成全生物科技 技术同事, and route 卸慧群档案 accordingly

• Owner: me
• Source: git-repo 2026-08-08 — 02-Clients/Agents/_known_associations.md (commit 4b237a82, Hermes Agent 2026-08-07 hook 4) maps 济南成全生物科技有限公司 (曹沛起) as the only CelVivo ClinoStar-listed agent in the 259-dealer China map (华北 + 山东 跨区重复登记). 02-Clients/Agents/董慧群.md (2026-07-28 commit 21491578) lists 董慧群 as CelVivo 产品技术同事 with agency: 待补.
• Due: unscheduled
• Status: open
• Notes: The 2026-08-07 hook 4 partial-resolution gave a likely candidate (济南成全生物科技 曹沛起 company) but the precise link to 董慧群 (and whether she is 济南成全的技术同事, or another dealer) is still unverified. Action: Robin to verify with 董慧群 directly via WeChat / 微信 (current open-question /open-questions.md agent-dong-huiqun-celvivo). Once confirmed: update 02-Clients/Agents/董慧群.md frontmatter agency field, and update /sources/agents.md "代理商品牌" column from "待补" to "济南成全生物科技 (曹沛起)". Until this is done, 董慧群's role in the 济南成全 book of business is unconfirmed.

distributors-2026-08-07-refresh: 落地 2026-08-07 全国经销商地图到 wiki + 跨工具

• Owner: me
• Source: git-repo 2026-08-08 — Obsidian vault 02-Clients/Agents/全国经销商地图-2026-0807.md + 7 区域分文件 (8-07 baseline, 259 dealers across 7 regions, net change -2 from 2026-07-24 baseline). Vault raw survives 2026-08-08 fetch as untracked files (commit 4b237a82 Lin Yongli "4 个经销商管理 Hook 升级").
• Due: unscheduled
• Status: open
• Notes: 8-07 baseline differs from 7-24 baseline in: (a) total 261 → 259 (华北 74 → 72); (b) 济南成全生物科技有限公司 (曹沛起) cross-region registration (华北 + 山东); (c) new _known_associations.md index maps CelVivo → 济南成全 / FemtoBiomed → 9X Bio → TriArm / 3Brain + Cellink → 0. Cross-reference: /sources/distributors-china-2026.md has been updated to the 8-07 baseline + new associations table; /sources/agents.md still needs the 董慧群 → 济南成全 link; /commitments.md has follow-up for 成都百乐 vs 成都立德赛 decision (open-question chengdu-baile-vs-lidesai-for-ou-xianhong). End-customer coverage for 3Brain / Cellink / FemtoBiomed still 0 in the 259 baseline — see open-question distributors-3brain-cellink-zero-coverage.

Completed recently